The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 15, 2018
Filed:
Aug. 19, 2015
Oncoethix Gmbh, Lucerne, CH;
Francesco Bertoni, Bellinzona, CH;
ONCOETHIX GMBH, Lucerne, CH;
Abstract
A method of treating lymphoma in a mammal comprises the step of: administering to a patient a pharmaceutical acceptable amount of a compound being a thienotriazolodiazepine compound of the Formula (1) wherein Ris alkyl having a carbon number of 1-4, Ris a hydrogen atom; a halogen atom; or alkyl having a carbon number of 1-4 optionally substituted by a halogen atom or a hydroxyl group, Ris a halogen atom; phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4 or cyano; —NR—(CH)—Rwherein Ris a hydrogen atom or alkyl having a carbon number of 1-4, m is an integer of 0-4, and Ris phenyl or pyridyl optionally substituted by a halogen atom; or —NR—CO—(CH)—Rwherein R is a hydrogen atom or alkyl having a carbon number of 1-4, n is an integer of 0-2, and Ris phenyl or pyridyl optionally substituted by a halogen atom, and Ris —(CH)—CO—NH—Rwherein a is an integer of 1-4, and Ris alkyl having a carbon number of 1-4; hydroxyalkyl having a carbon number of 1-4; alkoxy having a carbon number of 1-4; or phenyl or pyridyl optionally substituted by alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4, amino or a hydroxyl group or —(CH)—COORwherein b is an integer of 1-4, and Ris alkyl having a carbon number of 1-4, or a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof. The lymphoma to be treated is diffuse large B-cell lymphom (DLBCL) specifically selected from activated B-cell DLBCL (ABC-DLBCL) and germinal B-cell DLBCL (GBC-DLBCL).